SCHEMBL1999094

SCHEMBL1999094

N#Cc1cnc2ccccc2n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
PDE10A Q9Y233 1/20 0.47
CHEK1 O14757 1/20 0.45
ALDH1A1 P00352 6/20 0.44
HPGD P15428 5/20 0.44
NPSR1 Q6W5P4 2/20 0.44
KDM4E B2RXH2 3/20 0.43
GPR3 P46089 1/20 0.43
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
HTT P42858 7/20 0.41
PDGFRB P09619 1/20 0.41
PDGFRA P16234 1/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5845182 0.78 PDE10A (0.47) MAPTMEN1KMT2APDE10AALDH1A1
SCHEMBL6352308 0.78 PDE10A (0.47) MAPTMEN1KMT2APDE10AALDH1A1
SCHEMBL6008088 0.78 PDE10A (0.47) MAPTMEN1KMT2APDE10AALDH1A1
SCHEMBL95119 0.78 ALDH1A1 (0.47) MAPTMEN1KMT2APDE10AALDH1A1
SCHEMBL31526085 0.78 PDE10A (0.47) MAPTMEN1KMT2APDE10AALDH1A1
SCHEMBL2747071 0.78 PDE10A (0.47) MAPTMEN1KMT2APDE10AALDH1A1
SCHEMBL1997041 0.75 ALDH1A1 (0.45) MAPTMEN1KMT2ACHEK1ALDH1A1
SCHEMBL31184333 0.75 NQO2 (0.46) MAPTMEN1KMT2ACHEK1ALDH1A1
SCHEMBL20951862 0.75 HRH4 (0.44) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL15689092 0.75 PTGES (0.39) CHEK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116217500-B Cyano quinoxaline red light thermal excitation delayed fluorescent material, synthetic method and application thereof 黑龙江大学 2025-05-16 CN claimed
CN-116217500-A Cyano quinoxaline red light thermal excitation delayed fluorescent material, synthetic method and application thereof 黑龙江大学 2023-06-06 CN claimed
CN-113200929-B Cyano quinoxaline red light thermal excitation delayed fluorescent material, synthetic method and application thereof 黑龙江大学 2023-04-28 CN claimed
CN-113200929-A Cyanoquinoxaline red-light thermal excitation delayed fluorescent material, and synthesis method and application thereof 黑龙江大学 2021-08-03 CN claimed
US-10550203-B2 Polymers functionalized with heterocyclic nitrile compounds BRIDGESTONE CORPORATION (JP) 2020-02-04 US claimed
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
US-20180319905-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (JP) 2018-11-08 US claimed
US-20170015760-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (JP) 2017-01-19 US claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 US claimed
US-9469741-B2 Polymers functionalized with heterocyclic nitrile compounds BRIDGESTONE CORPORATION (JP) 2016-10-18 US claimed
CN-101874044-A Polymers functionalized with heterocyclic nitrile compounds BRIDGESTONE CORP 2010-10-27 CN claimed
EP-2203482-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS Bridgestone Corporation (JP) 2010-07-07 EP claimed
US-20100113756-A1 LUMINESCENT METAL COMPLEXES FOR MONITORING RENAL FUNCTION MALLINCKRODT INC. (US) 2010-05-06 US claimed
US-7674902-B2 Luminescent metal complexes for monitoring renal function MALLINCKRODT INC. (US) 2010-03-09 US claimed
WO-2009051702-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (JP) 2009-04-23 WO claimed
WO-2009051700-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (US) 2009-04-23 WO claimed
US-20090099325-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION 2009-04-16 US claimed
WO-2002094796-A2 BENZO[G]QUINOXALINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES AXXIMA PHARMACEUTICALS AG (DE) 2002-11-28 WO claimed
WO-1999009845-A1 IMIDAZOQUINOXALINE PROTEIN TYROSINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 1999-03-04 WO claimed
US-4925901-A STORAGE STAABILITY, ONIUM ION CATALYST THE DOW CHEMICAL COMPANY (US) 1990-05-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113756-A1 LUMINESCENT METAL COMPLEXES FOR MONITORING RENAL FUNCTION REN, GLS, ATP6V1B1 MAPT 4803/4885MEN1 246/4885KMT2A 3790/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR MAPT 150/4885MEN1 722/4885KMT2A 3227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.